LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Noninvasive detection of any-stage cancer using free glycosaminoglycans

Photo by nci from unsplash

Significance Multi-cancer early detection (MCED) is an emerging paradigm to curb cancer mortality by shifting stage at diagnosis through a single test capturing all cancer types when still confined to… Click to show full abstract

Significance Multi-cancer early detection (MCED) is an emerging paradigm to curb cancer mortality by shifting stage at diagnosis through a single test capturing all cancer types when still confined to their tissue of origin (stage I). Liquid biopsies based on genomic biomarkers could make MCED realistic, but limitations include ~10% stage I sensitivity in validation studies; the inability to detect specific types like gliomas; complex assays; and potential overdiagnosis. Here, we demonstrate the potential of free glycosaminoglycan profiles (GAGomes) as metabolic biomarkers for MCED across 14 cancer types. In a validation study, plasma and urine GAGomes doubled the stage I sensitivity reported by state-of-the-art genomics biomarkers and detected poor prognosis cancers. As such, this simple assay could accelerate MCED implementation.

Keywords: detection stage; stage cancer; stage; cancer; noninvasive detection

Journal Title: Proceedings of the National Academy of Sciences of the United States of America
Year Published: 2022

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.